Latest Diagnostics News

Page 37 of 40
Optiscan Imaging has initiated a pivotal pre-clinical gastrointestinal study in Germany using its first flexible prototype, aiming to revolutionize real-time GI tract imaging and diagnostics.
Ada Torres
Ada Torres
3 Feb 2025
Rewardle Holdings reports a strong December quarter with positive cash flow and a significant valuation uplift in its CloudHolter partnership, underpinning its multi-pronged growth strategy.
Sophie Babbage
Sophie Babbage
31 Jan 2025
Cleo Diagnostics reports steady progress in its U.S. and Australian clinical trials for an ovarian cancer blood test, maintaining a solid cash reserve of A$7.3 million as it prepares for FDA submission.
Ada Torres
Ada Torres
31 Jan 2025
Clarity Pharmaceuticals reports robust progress in its SECURE trial and secures FDA Fast Track Designation for its diagnostic agent 64Cu-SAR-bisPSMA, underpinning its growth and innovation in prostate cancer treatment.
Victor Sage
Victor Sage
31 Jan 2025
BCAL Diagnostics is poised to launch its innovative BREASTEST® breast cancer diagnostic test in early 2025, backed by recent NATA accreditation, patent acceptance, and a $2.6 million R&D tax offset.
Ada Torres
Ada Torres
31 Jan 2025
IMEXHS Limited reported a robust 34% increase in FY24 revenue to $26.5 million, driven by new contracts in Colombia and Peru that boosted its Annual Recurring Revenue to $30 million. Despite a slight EBITDA shortfall due to a bad debt expense, the company highlighted operational improvements and strengthened its regional footprint.
Ada Torres
Ada Torres
31 Jan 2025
Genetic Signatures reported a robust 190% increase in quarterly sales to $3.8 million, driven by strong respiratory testing demand in Australia and strategic UK deployments. Despite longer US sales cycles, the company maintains a solid $40.8 million cash position and advances R&D on its 3base® platform.
Ada Torres
Ada Torres
31 Jan 2025
INOVIQ's December quarterly update reveals significant progress in its cancer diagnostic and therapeutic programs, including a highly accurate ovarian cancer screening test and promising breast cancer therapeutics, supported by growing EXO-NET customer adoption and a solid cash position.
Ada Torres
Ada Torres
31 Jan 2025
Lumos Diagnostics reported a robust Q2 FY25 with a 71% revenue increase to US$2.9 million, driven by strong product and service sales, alongside a strategic US$3 million BARDA partnership to advance its FebriDx test.
Ada Torres
Ada Torres
31 Jan 2025
Optiscan Imaging Ltd reported a productive December quarter, marked by key product developments, strategic partnerships, and a stronger cash position, setting the stage for growth in medical and veterinary imaging markets.
Victor Sage
Victor Sage
31 Jan 2025
Telix Pharmaceuticals has completed a strategic acquisition of ImaginAb, gaining next-generation therapeutic assets and a novel biologics platform to expand its oncology pipeline and R&D capabilities.
Ada Torres
Ada Torres
31 Jan 2025
Optiscan Imaging Ltd has secured a $1.775 million R&D tax refund for FY24, more than doubling last year’s amount thanks to expanded claims on overseas research. The boost will fund ongoing development of its cutting-edge confocal laser endomicroscopy technology.
Ada Torres
Ada Torres
31 Jan 2025